Tarsus to Acquire Alkeus Pharmaceuticals for Up to $800 Million, Securing Late-Stage Stargardt Disease Drug Gildeuretinol
核心洞察
Tarsus Pharmaceuticals announced plans to acquire Alkeus Pharmaceuticals (搜索) for $270 million in cash and $180 million in stock, with up to $350 million in additional milestone payments.
The deal centers on gildeuretinol (ALK-001), a late-stage investigational therapy for Stargardt disease (搜索) that has received Breakthrough Therapy, Rare Pediatric Disease, Fast Track, and Orphan Drug designations from the FDA.
In the TEASE-1 study, gildeuretinol slowed the growth rate of atrophic retinal lesions by 29.5% versus placebo, and TEASE-3 interim data showed a 21% reduction in lesion growth rate (p<0.001).
Tarsus Pharmaceuticals has agreed to acquire Alkeus Pharmaceuticals (搜索) in a deal valued at up to $800 million, the companies announced Thursday. The transaction brings Tarsus a late-stage investigational therapy for Stargardt disease (搜索), a genetic retinal condition with no currently available treatments, and marks the end of an unusual 16-year journey for the Cambridge, Massachusetts-based startup.
Under the terms of the agreement, Tarsus will pay $270 million in cash and $180 million in common stock at closing, with Alkeus stockholders eligible for up to $350 million in additional milestone payments upon regulatory approval and first commercial sales of gildeuretinol. Alkeus shareholders, which include Bain Capital Life Sciences and TCGX, may also receive low single-digit tiered descending royalties as a percentage of net sales. The deal has been approved by both companies' boards of directors and Alkeus stockholders, with closing expected later in 2026, subject to customary conditions.
Gildeuretinol: A Novel Approach to Stargardt Disease (搜索)
Gildeuretinol acetate (ALK-001) is a new molecular entity designed to reduce the dimerization of vitamin A without modulating the visual cycle. In Stargardt disease (搜索), a genetic defect alters how the body processes vitamin A needed for retinal cells, leading to the formation of yellowish clumps in the eyes and progressive vision loss. Gildeuretinol is essentially a modified version of vitamin A that halts the chemical reaction responsible for those damaging deposits.
"It's the most elegant possible way for a drug" to work, Josh Boger—the Merck & Co. chemist who founded Vertex Pharmaceuticals and served as Alkeus's executive chairman—told BioPharma Dive in 2023, calling gildeuretinol potentially "the most perfect drug I've ever seen."
The drug has been evaluated across four clinical trials as part of the Tolerability and Effects of ALK-001 on Stargardt diseasE (搜索) (TEASE) program. In the TEASE-1 study, gildeuretinol slowed the growth rate of atrophic retinal lesion area by 21.6% versus untreated patients, while demonstrating a 29.5% reduction in the growth rate of atrophic lesions. Interim data from TEASE-3 showed a 21% reduction in the growth rate of retinal atrophic lesions (p<0.001, square root units, translating to a 28% effect for untransformed areas) compared with untreated patients.
More than 400 patients have received the drug to date, with some remaining on therapy for as long as seven years. Investigators have not detected any treatment-related effects on night or color vision, or on eye sensitivity when shifting from bright to dark environments, according to Tarsus.
Regulatory Momentum and Ongoing Development
Gildeuretinol has secured four FDA designations for Stargardt disease (搜索): Breakthrough Therapy, Rare Pediatric Disease, Fast Track, and Orphan Drug. The drug recently advanced into a pivotal phase 3 NORTHSTAR trial (NCT07419334), with the first patient dosed just months ago. Beyond Stargardt, gildeuretinol is also under investigation for geographic atrophy (搜索) secondary to age-related macular degeneration, having been evaluated in the phase 3 SAGA trial.
"We believe gildeuretinol has the potential to be a transformational medicine for Stargardt disease (搜索)," said Tarsus CEO Bobby Azamian in a statement.
A Startup's Unconventional Path
The acquisition caps a distinctive trajectory for Alkeus, which was founded in 2010 and run largely by a single person, Leonide Saad, for much of its existence. Saad used his own money to fund the company until raising a $2 million Series A round in 2011. After winning the MassChallenge biotech startup competition, Saad recruited Boger as executive chairman in 2012. The company later secured a $150 million Series B round and advanced gildeuretinol through mid-stage testing with grant support.
Strategic Expansion for Tarsus
The Alkeus deal represents Tarsus's second acquisition announcement in recent months, following its disclosed intention to acquire iRenix Medical and its investigational ocular antiseptic. The transaction significantly expands Tarsus's footprint in the retina space, adding a late-stage asset targeting a disease with high unmet medical need.